These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33250701)

  • 1. Pembrolizumab-Induced Delayed-Onset Hepatitis.
    Kanaoka K; Moriizumi K; Okada H; Iwahashi K; Tsuji H; Yasuoka H; Minami S
    Case Rep Gastroenterol; 2020; 14(3):586-592. PubMed ID: 33250701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pulse steroid therapy to treat liver injury with risk of liver failure due to immune-related adverse events:a case report].
    Hashiguchi M; Tamai T; Nakazawa J; Iwashita Y; Nasu Y; Funakawa K; Hori T; Sueyoshi K; Tsubouchi H; Ido A
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(2):175-182. PubMed ID: 33563858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101753. PubMed ID: 36217354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101773. PubMed ID: 36408484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy.
    Zen Y; Yeh MM
    Semin Diagn Pathol; 2019 Nov; 36(6):434-440. PubMed ID: 31358424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab-Induced Meningoencephalitis: A Brain Autopsy Case.
    Minami S; Okada H; Ihara S; Tsuji H; Yamadera M; Yasuoka H
    J Med Cases; 2021 Sep; 12(9):359-365. PubMed ID: 34527106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy.
    Liang I; Chu G; Zielinski R
    Case Rep Oncol; 2023; 16(1):182-187. PubMed ID: 37013108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes.
    Zen Y; Chen YY; Jeng YM; Tsai HW; Yeh MM
    Histopathology; 2020 Feb; 76(3):470-480. PubMed ID: 31550390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folliculotropic Mycosis Fungoides Associated with Autoimmune Hepatitis.
    Radoš J; Jerković Gulin S; Dotlić S; Bašić Kinda S; Čeović R
    Acta Dermatovenerol Croat; 2017 Oct; 25(3):248-250. PubMed ID: 29252180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
    Yang H; Zhou C; Yuan F; Guo L; Yang L; Shi Y; Zhang J
    Front Med (Lausanne); 2021; 8():719236. PubMed ID: 34712676
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report.
    Hayashi A; Nakamichi S; Nakayama Y; Nagano A; Mikami E; Takano N; Tozuka T; Matsumoto M; Miyanaga A; Noro R; Terasaki Y; Kubota K; Seike M; Gemma A
    Onco Targets Ther; 2022; 15():637-642. PubMed ID: 35698605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer.
    Asatani S; Kanda T; Honda M; Ishii T; Yamana Y; Kaneko T; Mizutani T; Takahashi H; Kumagawa M; Sasaki R; Masuzaki R; Kanezawa S; Matsumoto N; Nirei K; Yamagami H; Moriyama M
    JGH Open; 2021 Jun; 5(6):722-724. PubMed ID: 34124393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab.
    Honma Y; Shibata M; Gohda T; Matsumiya H; Kumamoto K; Miyama A; Morino K; Koya Y; Taira A; Shinohara S; Hayashi T; Kusanaga M; Oe S; Miyagawa K; Abe S; Tanaka F; Harada M
    Intern Med; 2021 Jun; 60(12):1847-1853. PubMed ID: 33456046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibitor-induced gastritis followed by delayed severe hepatitis in a patient with lung metastases of head and neck squamous cell carcinoma: a case report.
    Otsuka T; Hashii Y; Murayama S; Ishizuka Y; Kojitani Y; Nishio M; Kudo T
    Front Oncol; 2023; 13():1164236. PubMed ID: 37251947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
    Almutairi AR; McBride A; Slack M; Erstad BL; Abraham I
    Front Oncol; 2020; 10():91. PubMed ID: 32117745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.